▎药明康德内容团队编辑
作为药明康德旗下专注于细胞和基因疗法的CTDMO,药明生基致力于加速和变革基因和细胞治疗及其他高端治疗的开发、测试、生产和商业化。药明生基能够助力全球客户将更多创新疗法早日推向市场,造福病患。如您有相关业务需求,欢迎点击下方图片填写具体信息。
▲如您有任何业务需求,请长按扫描上方二维码,或点击文末“阅读原文/Read more”,即可访问业务对接平台,填写业务需求信息
参考资料:
[1] Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis. Retrieved December 9, 2022, from https://www.globenewswire.com/news-release/2022/12/08/2570658/0/en/Autolus-Therapeutics-announces-pivotal-Phase-2-FELIX-clinical-trial-has-met-primary-endpoint-at-interim-analysis.html
[2] Autolus Announces Pricing of Public Offering. Retrieved December 9, 2022, from https://autolus.gcs-web.com/news-releases/news-release-details/autolus-announces-pricing-public-offering-2
[3] Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences. Retrieved December 9, 2022, from https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-receive-70-million-milestone-payments
免责声明:药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的,文中观点不代表药明康德立场,亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导,请前往正规医院就诊。
版权说明:本文来自药明康德内容团队,欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”,获取转载须知。
分享,点赞,在看,聚焦全球生物医药健康创新